ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Dan­ish biotech Ad­cen­do is join­ing the an­ti­body-drug con­ju­gate megaround train.

Ad­cen­do has cor­ralled a $135 mil­lion Se­ries B led by TCGX. And ac­cord­ing to an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER